Literature DB >> 12126785

Risk of macrovascular and microvascular complications in Type 2 diabetes: results of longitudinal study design.

Boguslawa Nazimek-Siewniak1, DariuszK Moczulski, Wladyslaw Grzeszczak.   

Abstract

Type 2 diabetes is associated with the increased risk of microvascular and macrovascular complications. The aim of this study was to determine risk factors for the development of long-term complications of Type 2 diabetes. We analyzed medical records of all patients, who came with newly diagnosed Type 2 diabetes to one regional outpatient diabetes clinic from 1980 to 1994 (n=2175). The data, such as fasting plasma glucose, total cholesterol, triglyceride, blood pressure and body mass index (BMI), were assessed. Also, the time from the diagnosis of Type 2 diabetes to the occurrence of complications was obtained. Using the regression model in the survival analysis, we examined which of the risk factors determined the rate of the development of nephropathy, proliferative retinopathy, cardiovascular disease and stroke. Patients with higher fasting plasma glucose and higher mean blood pressure had higher risk of developing nephropathy and proliferative retinopathy. Higher mean arterial blood pressure was associated with higher rate of stroke and cardiovascular disease. High total cholesterol increased the hazard of coronary artery disease and proliferative retinopathy. In conclusion, blood pressure and fasting plasma glucose are major risk factors for microvascular complications in Type 2 diabetes. An increased blood pressure determined the macrovascular complications in Type 2 diabetes, but the effect of increased fasting plasma glucose could not be proved.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12126785     DOI: 10.1016/s1056-8727(01)00184-2

Source DB:  PubMed          Journal:  J Diabetes Complications        ISSN: 1056-8727            Impact factor:   2.852


  27 in total

1.  Health-related quality of life deficits associated with diabetes and comorbidities in a Canadian National Population Health Survey.

Authors:  Sheri L Maddigan; David H Feeny; Jeffrey A Johnson
Journal:  Qual Life Res       Date:  2005-06       Impact factor: 4.147

2.  Emerging Pharmacological Targets for the Treatment of Nonalcoholic Fatty Liver Disease, Insulin Resistance, and Type 2 Diabetes.

Authors:  Leigh Goedeke; Rachel J Perry; Gerald I Shulman
Journal:  Annu Rev Pharmacol Toxicol       Date:  2019-01-06       Impact factor: 13.820

3.  Improving the Pharmacokinetics of GPR40/FFA1 Full Agonists.

Authors:  Xiaohui Du; Paul J Dransfield; Daniel C-H Lin; Simon Wong; Yingcai Wang; Zhongyu Wang; Todd Kohn; Ming Yu; Sean P Brown; Marc Vimolratana; Liusheng Zhu; An-Rong Li; Yongli Su; Xianyun Jiao; Jiwen Jim Liu; Gayathri Swaminath; Thanhvien Tran; Jian Luo; Run Zhuang; Jane Zhang; Qi Guo; Frank Li; Richard Connors; Julio C Medina; Jonathan B Houze
Journal:  ACS Med Chem Lett       Date:  2014-02-03       Impact factor: 4.345

4.  Potent and Orally Bioavailable GPR142 Agonists as Novel Insulin Secretagogues for the Treatment of Type 2 Diabetes.

Authors:  Narihiro Toda; Xiaolin Hao; Yasuyuki Ogawa; Kozo Oda; Ming Yu; Zice Fu; Yi Chen; Yongjae Kim; Mike Lizarzaburu; Sarah Lively; Shauna Lawlis; Michiko Murakoshi; Futoshi Nara; Nobuaki Watanabe; Jeff D Reagan; Hui Tian; Angela Fu; Alykhan Motani; Qingxiang Liu; Yi-Jyun Lin; Run Zhuang; Yumei Xiong; Peter Fan; Julio Medina; Leping Li; Masanori Izumi; Ryo Okuyama; Satoshi Shibuya
Journal:  ACS Med Chem Lett       Date:  2013-06-17       Impact factor: 4.345

Review 5.  Health technologies for monitoring and managing diabetes: a systematic review.

Authors:  Elizabeth Russell-Minda; Jeffrey Jutai; Mark Speechley; Kaitlin Bradley; Anna Chudyk; Robert Petrella
Journal:  J Diabetes Sci Technol       Date:  2009-11-01

6.  Ocular circulation in diabetic patients with coronary artery disease.

Authors:  Sayuri Fujioka; Kaoruko Karashima; Norikiyo Nishikawa; Yoshihiro Saito
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2006-02       Impact factor: 3.117

7.  C5-Alkyl-2-methylurea-Substituted Pyridines as a New Class of Glucokinase Activators.

Authors:  Xiaohui Du; Ronald J Hinklin; Yumei Xiong; Paul Dransfield; Jaehyeon Park; Todd J Kohn; Vatee Pattaropong; SuJen Lai; Zice Fu; Xianyun Jiao; David Chow; Lixia Jin; Jasmine Davda; Murielle M Veniant; Deborah A Anderson; Brian R Baer; Josef R Bencsik; Steven A Boyd; Mark Joseph Chicarelli; Peter J Mohr; Bin Wang; Kevin R Condroski; Walter E DeWolf; Marion Conn; Thanhvien Tran; Jerry Yang; Thomas D Aicher; Julio C Medina; Peter Coward; Jonathan B Houze
Journal:  ACS Med Chem Lett       Date:  2014-11-22       Impact factor: 4.345

8.  Factors associated with psychological and behavioral functioning in people with type 2 diabetes living in France.

Authors:  Stephanie Boini; Marie-Line Erpelding; Anne Fagot-Campagna; Mounir Mesbah; Judith Chwalow; Alfred Penfornis; Vincent Coliche; Etienne Mollet; Keith Meadows; Serge Briançon
Journal:  Health Qual Life Outcomes       Date:  2010-11-02       Impact factor: 3.186

9.  Discovery of a Potent and Orally Efficacious TGR5 Receptor Agonist.

Authors:  Sameer Agarwal; Amit Patil; Umesh Aware; Prashant Deshmukh; Brijesh Darji; Santosh Sasane; Kalapatapu V V M Sairam; Priyanka Priyadarsiny; Poonam Giri; Harilal Patel; Suresh Giri; Mukul Jain; Ranjit C Desai
Journal:  ACS Med Chem Lett       Date:  2015-11-20       Impact factor: 4.345

10.  Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes.

Authors:  James F List; Vincent Woo; Enrique Morales; Weihua Tang; Fred T Fiedorek
Journal:  Diabetes Care       Date:  2008-12-29       Impact factor: 17.152

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.